Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).

Rioux N, Smith S, Korpal M, O'Shea M, Prajapati S, Zheng GZ, Warmuth M, Smith PG.

Cancer Chemother Pharmacol. 2018 Nov 1. doi: 10.1007/s00280-018-3716-3. [Epub ahead of print]

PMID:
30386887
2.

Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.

Rioux N, Kim A, Nix D, Bowser T, Warmuth M, Smith PG, Schindler J.

Cancer Chemother Pharmacol. 2018 Oct 27. doi: 10.1007/s00280-018-3708-3. [Epub ahead of print]

PMID:
30368584
3.

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, Groell JM, Grotzfeld RM, Hassan AQ, Henry C, Iyer V, Jones D, Lombardo F, Loo A, Manley PW, Pellé X, Rummel G, Salem B, Warmuth M, Wylie AA, Zoller T, Marzinzik AL, Furet P.

J Med Chem. 2018 Sep 27;61(18):8120-8135. doi: 10.1021/acs.jmedchem.8b01040. Epub 2018 Sep 7.

PMID:
30137981
4.

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.

Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, Agoulnik S, Bolduc DM, Buonamici S, Caleb B, Das S, Eckley S, Fekkes P, Hao MH, Hart A, Houtman R, Irwin S, Joshi JJ, Karr C, Kim A, Kumar N, Kumar P, Kuznetsov G, Lai WG, Larsen N, Mackenzie C, Martin LA, Melchers D, Moriarty A, Nguyen TV, Norris J, O'Shea M, Pancholi S, Prajapati S, Rajagopalan S, Reynolds DJ, Rimkunas V, Rioux N, Ribas R, Siu A, Sivakumar S, Subramanian V, Thomas M, Vaillancourt FH, Wang J, Wardell S, Wick MJ, Yao S, Yu L, Warmuth M, Smith PG, Zhu P, Korpal M.

Cancer Discov. 2018 Sep;8(9):1176-1193. doi: 10.1158/2159-8290.CD-17-1229. Epub 2018 Jul 10.

PMID:
29991605
5.

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.

Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S.

Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19.

PMID:
29457796
6.

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients.

Agrawal AA, Seiler M, Brinton LT, Mantel R, Lapalombella R, Woyach JA, Johnson AJ, Zhu P, Warmuth M, Yu L, Byrd JC, Smith PG, Blachly JS, Buonamici S.

Blood Adv. 2017 Jun 14;1(15):995-1000. doi: 10.1182/bloodadvances.2017007062. eCollection 2017 Jun 27.

7.

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.

Joshi JJ, Coffey H, Corcoran E, Tsai J, Huang CL, Ichikawa K, Prajapati S, Hao MH, Bailey S, Wu J, Rimkunas V, Karr C, Subramanian V, Kumar P, MacKenzie C, Hurley R, Satoh T, Yu K, Park E, Rioux N, Kim A, Lai WG, Yu L, Zhu P, Buonamici S, Larsen N, Fekkes P, Wang J, Warmuth M, Reynolds DJ, Smith PG, Selvaraj A.

Cancer Res. 2017 Dec 15;77(24):6999-7013. doi: 10.1158/0008-5472.CAN-17-1865.

PMID:
29247039
8.

Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion.

Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, Yu L, Chmielecki J.

PLoS One. 2017 Nov 9;12(11):e0176181. doi: 10.1371/journal.pone.0176181. eCollection 2017.

9.

Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Korpal M, Puyang X, Jeremy Wu Z, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Julie Joshi J, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, Henry R, Selvaraj A, Davis A, Bloudoff K, Douglas J, Kiss B, Roberts M, Fazli L, Black PC, Fekkes P, Smith PG, Warmuth M, Yu L, Hao MH, Larsen N, Daugaard M, Zhu P.

Nat Commun. 2017 Jul 24;8(1):103. doi: 10.1038/s41467-017-00147-w.

10.

Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.

Teng T, Tsai JH, Puyang X, Seiler M, Peng S, Prajapati S, Aird D, Buonamici S, Caleb B, Chan B, Corson L, Feala J, Fekkes P, Gerard B, Karr C, Korpal M, Liu X, T Lowe J, Mizui Y, Palacino J, Park E, Smith PG, Subramanian V, Wu ZJ, Zou J, Yu L, Chicas A, Warmuth M, Larsen N, Zhu P.

Nat Commun. 2017 May 25;8:15522. doi: 10.1038/ncomms15522.

11.

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.

Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR.

Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22.

PMID:
28329763
12.

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.

Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD.

Nature. 2016 Jul 7;535(7610):148-52. Epub 2016 Jun 29.

PMID:
27362227
13.

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms.

Korpal M, Feala J, Puyang X, Zou J, Ramos AH, Wu J, Baumeister T, Yu L, Warmuth M, Zhu P.

J Vis Exp. 2015 Dec 9;(106):e52879. doi: 10.3791/52879.

14.

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.

Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, Bailey SL, Bhavsar EB, Chan B, Colla S, Corson L, Feala J, Fekkes P, Ichikawa K, Keaney GF, Lee L, Kumar P, Kunii K, MacKenzie C, Matijevic M, Mizui Y, Myint K, Park ES, Puyang X, Selvaraj A, Thomas MP, Tsai J, Wang JY, Warmuth M, Yang H, Zhu P, Garcia-Manero G, Furman RR, Yu L, Smith PG, Buonamici S.

Cell Rep. 2015 Nov 3;13(5):1033-45. doi: 10.1016/j.celrep.2015.09.053. Epub 2015 Oct 22.

15.

Planned and ongoing projects (pop) database: development and results.

Wild C, Erdös J, Warmuth M, Hinterreiter G, Krämer P, Chalon P.

Int J Technol Assess Health Care. 2014 Nov;30(5):497-503. doi: 10.1017/S0266462314000567.

PMID:
25747558
16.

Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line.

Arai K, Buonamici S, Chan B, Corson L, Endo A, Gerard B, Hao MH, Karr C, Kira K, Lee L, Liu X, Lowe JT, Luo T, Marcaurelle LA, Mizui Y, Nevalainen M, O'Shea MW, Park ES, Perino SA, Prajapati S, Shan M, Smith PG, Tivitmahaisoon P, Wang JY, Warmuth M, Wu KM, Yu L, Zhang H, Zheng GZ, Keaney GF.

Org Lett. 2014 Nov 7;16(21):5560-3. doi: 10.1021/ol502556c. Epub 2014 Oct 26.

PMID:
25376106
17.

NAMPT is the cellular target of STF-31-like small-molecule probes.

Adams DJ, Ito D, Rees MG, Seashore-Ludlow B, Puyang X, Ramos AH, Cheah JH, Clemons PA, Warmuth M, Zhu P, Shamji AF, Schreiber SL.

ACS Chem Biol. 2014 Oct 17;9(10):2247-54. doi: 10.1021/cb500347p. Epub 2014 Aug 7.

18.

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY.

J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26.

PMID:
23742252
19.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA.

Nature. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003. Erratum in: Nature. 2012 Dec 13;492(7428):290.

20.

Reducing RF-related heating of cardiac pacemaker leads in MRI: implementation and experimental verification of practical design changes.

Nordbeck P, Fidler F, Friedrich MT, Weiss I, Warmuth M, Gensler D, Herold V, Geistert W, Jakob PM, Ertl G, Ritter O, Ladd ME, Bauer WR, Quick HH.

Magn Reson Med. 2012 Dec;68(6):1963-72. doi: 10.1002/mrm.24197. Epub 2012 Mar 1.

21.

MR safety: fast T₁ thermometry of the RF-induced heating of medical devices.

Gensler D, Fidler F, Ehses P, Warmuth M, Reiter T, Düring M, Ritter O, Ladd ME, Quick HH, Jakob PM, Bauer WR, Nordbeck P.

Magn Reson Med. 2012 Nov;68(5):1593-9. doi: 10.1002/mrm.24171. Epub 2012 Jan 27.

22.

Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults.

Warmuth M, Mad P, Wild C.

Acta Anaesthesiol Scand. 2012 May;56(5):539-48. doi: 10.1111/j.1399-6576.2011.02586.x. Epub 2011 Dec 12. Review.

PMID:
22150561
23.

Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL.

Decker S, Zirlik K, Djebatchie L, Hartmann D, Ihorst G, Schmitt-Graeff A, Herchenbach D, Jumaa H, Warmuth M, Veelken H, Dierks C.

Blood. 2012 Jan 26;119(4):997-1007. doi: 10.1182/blood-2011-06-359075. Epub 2011 Nov 30.

24.

Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.

Scholer-Dahirel A, Schlabach MR, Loo A, Bagdasarian L, Meyer R, Guo R, Woolfenden S, Yu KK, Markovits J, Killary K, Sonkin D, Yao YM, Warmuth M, Sellers WR, Schlegel R, Stegmeier F, Mosher RE, McLaughlin ME.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17135-40. doi: 10.1073/pnas.1104182108. Epub 2011 Sep 23.

25.

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion.

Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin WG Jr, Spardy N, Hahn WC, Hoshida Y, Ogino S, DePinho RA, Chin L, Garraway LA, Fuchs CS, Baselga J, Tabernero J, Gabriel S, Lander ES, Getz G, Meyerson M.

Nat Genet. 2011 Sep 4;43(10):964-968. doi: 10.1038/ng.936.

26.

Feasibility of contrast-enhanced and nonenhanced MRI for intraprocedural and postprocedural lesion visualization in interventional electrophysiology: animal studies and early delineation of isthmus ablation lesions in patients with typical atrial flutter.

Nordbeck P, Hiller KH, Fidler F, Warmuth M, Burkard N, Nahrendorf M, Jakob PM, Quick HH, Ertl G, Bauer WR, Ritter O.

Circ Cardiovasc Imaging. 2011 May;4(3):282-94. doi: 10.1161/CIRCIMAGING.110.957670. Epub 2011 Mar 17.

PMID:
21415125
27.

Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer" [Eur Urol 2010;58:803-15].

Warmuth M, Johansson T, Mad P.

Eur Urol. 2011 Mar;59(3):476. doi: 10.1016/j.eururo.2010.11.042. Epub 2010 Dec 8. No abstract available.

PMID:
28065364
28.

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.

Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, Lenz P, Waters NJ, Schuler W, Dörken B, Yao YM, Warmuth M, Lenz G, Stegmeier F.

Cancer Res. 2011 Apr 1;71(7):2643-53. doi: 10.1158/0008-5472.CAN-10-2525. Epub 2011 Feb 15.

29.

Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky SJ, Murtie J, Kelleher JF, Warmuth M, Sellers WR, Roberts CW, Dorsch M.

Nat Med. 2010 Dec;16(12):1429-33. doi: 10.1038/nm.2251. Epub 2010 Nov 14.

30.

Allosteric inhibition of BCR-ABL.

Hassan AQ, Sharma SV, Warmuth M.

Cell Cycle. 2010 Sep 15;9(18):3710-4. doi: 10.4161/cc.9.18.13232. Epub 2010 Sep 3. Review.

PMID:
20930519
31.

Hedgehog pathway activation in chronic myeloid leukemia.

Jagani Z, Dorsch M, Warmuth M.

Cell Cycle. 2010 Sep 1;9(17):3449-56. Review.

PMID:
20928937
32.

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M.

Sci Transl Med. 2010 Sep 29;2(51):51ra70. doi: 10.1126/scitranslmed.3001599.

33.

Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer.

Warmuth M, Johansson T, Mad P.

Eur Urol. 2010 Dec;58(6):803-15. doi: 10.1016/j.eururo.2010.09.009. Epub 2010 Sep 17. Review. Erratum in: Eur Urol. 2011 Mar;59(3):476.

PMID:
20864250
34.

Impact of imaging landmark on the risk of MRI-related heating near implanted medical devices like cardiac pacemaker leads.

Nordbeck P, Ritter O, Weiss I, Warmuth M, Gensler D, Burkard N, Herold V, Jakob PM, Ertl G, Ladd ME, Quick HH, Bauer WR.

Magn Reson Med. 2011 Jan;65(1):44-50. doi: 10.1002/mrm.22592.

35.

The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease.

Dierks C, Adrian F, Fisch P, Ma H, Maurer H, Herchenbach D, Forster CU, Sprissler C, Liu G, Rottmann S, Guo GR, Katja Z, Veelken H, Warmuth M.

Cancer Res. 2010 Aug 1;70(15):6193-204. doi: 10.1158/0008-5472.CAN-08-3719.

36.

A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.

Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T.

J Med Chem. 2010 Aug 12;53(15):5439-48. doi: 10.1021/jm901808w.

37.

The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells.

Jagani Z, Wiederschain D, Loo A, He D, Mosher R, Fordjour P, Monahan J, Morrissey M, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M.

Cancer Res. 2010 Jul 1;70(13):5528-38. doi: 10.1158/0008-5472.CAN-09-4229. Epub 2010 Jun 8.

38.

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.

Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, Han D, Liu J, Englund NP, Wang Y, Peukert S, Miller-Moslin K, Yuan J, Guo R, Matsumoto M, Vattay A, Jiang Y, Tsao J, Sun F, Pferdekamper AC, Dodd S, Tuntland T, Maniara W, Kelleher JF 3rd, Yao YM, Warmuth M, Williams J, Dorsch M.

ACS Med Chem Lett. 2010 Mar 16;1(3):130-4. doi: 10.1021/ml1000307. eCollection 2010 Jun 10.

39.

Targeted cancer therapies in the twenty-first century: lessons from imatinib.

Stegmeier F, Warmuth M, Sellers WR, Dorsch M.

Clin Pharmacol Ther. 2010 May;87(5):543-52. doi: 10.1038/clpt.2009.297. Epub 2010 Mar 17. Review.

PMID:
20237469
40.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenholm A, Fendrich G, Strauss A, Zhang J, Gray NS, Adrian F, Warmuth M, Pelle X, Grotzfeld R, Berst F, Marzinzik A, Cowan-Jacob SW, Furet P, Mestan J.

Biochim Biophys Acta. 2010 Mar;1804(3):454-62. doi: 10.1016/j.bbapap.2009.12.009.

PMID:
20152788
41.

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS.

Nature. 2010 Jan 28;463(7280):501-6. doi: 10.1038/nature08675. Epub 2010 Jan 13.

42.

Feasibility of real-time MRI with a novel carbon catheter for interventional electrophysiology.

Nordbeck P, Bauer WR, Fidler F, Warmuth M, Hiller KH, Nahrendorf M, Maxfield M, Wurtz S, Geistert W, Broscheit J, Jakob PM, Ritter O.

Circ Arrhythm Electrophysiol. 2009 Jun;2(3):258-67. doi: 10.1161/CIRCEP.108.778357. Epub 2009 Mar 6.

PMID:
19808476
43.

A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function.

Barouch-Bentov R, Che J, Lee CC, Yang Y, Herman A, Jia Y, Velentza A, Watson J, Sternberg L, Kim S, Ziaee N, Miller A, Jackson C, Fujimoto M, Young M, Batalov S, Liu Y, Warmuth M, Wiltshire T, Cooke MP, Sauer K.

Mol Cell. 2009 Jan 16;33(1):43-52. doi: 10.1016/j.molcel.2008.12.024.

44.

Measuring RF-induced currents inside implants: Impact of device configuration on MRI safety of cardiac pacemaker leads.

Nordbeck P, Weiss I, Ehses P, Ritter O, Warmuth M, Fidler F, Herold V, Jakob PM, Ladd ME, Quick HH, Bauer WR.

Magn Reson Med. 2009 Mar;61(3):570-8. doi: 10.1002/mrm.21881.

45.

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.

Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, Trussell C, Schmitt-Graeff A, Landwerlin K, Veelken H, Warmuth M.

Cancer Cell. 2008 Sep 9;14(3):238-49. doi: 10.1016/j.ccr.2008.08.003.

46.

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.

Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, Didonato M, Nagle A, Warmuth M, Balk SP, Peters EC, Gray NS.

Bioorg Med Chem Lett. 2008 Nov 15;18(22):5916-9. doi: 10.1016/j.bmcl.2008.07.062. Epub 2008 Jul 18.

47.

Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies.

Jia Y, Gu XJ, Brinker A, Warmuth M.

Expert Opin Drug Discov. 2008 Aug;3(8):959-78. doi: 10.1517/17460441.3.8.959.

PMID:
23484970
48.

Spatial distribution of RF-induced E-fields and implant heating in MRI.

Nordbeck P, Fidler F, Weiss I, Warmuth M, Friedrich MT, Ehses P, Geistert W, Ritter O, Jakob PM, Ladd ME, Quick HH, Bauer WR.

Magn Reson Med. 2008 Aug;60(2):312-9. doi: 10.1002/mrm.21475.

49.

MRI thermometry: Fast mapping of RF-induced heating along conductive wires.

Ehses P, Fidler F, Nordbeck P, Pracht ED, Warmuth M, Jakob PM, Bauer WR.

Magn Reson Med. 2008 Aug;60(2):457-61. doi: 10.1002/mrm.21417.

50.

Relative loss bounds for single neurons.

Helmbold DP, Kivinen J, Warmuth MK.

IEEE Trans Neural Netw. 1999;10(6):1291-304. doi: 10.1109/72.809075.

PMID:
18252631

Supplemental Content

Loading ...
Support Center